Healthcare Industry News: anastomosis
News Release - January 31, 2007
Novadaq announces independent clinical results presented at STSResults Support Use of SPY System for Reduction of Post Operative Complications
TORONTO, Jan. 31 (HSMN NewsFeed) - Novadaq® Technologies Inc. (TSX: NDQ ), a developer of medical imaging systems for the operating room, announced today that the results of an independent study from Sunnybrook Health Sciences Centre, Toronto, Canada, were presented at the 43rd Annual Society of Thoracic Surgeons Annual Meeting in San Diego. These results confirm that the use of the SPY® System during Coronary Artery Bypass Surgery (CABG) can lead to significantly improved clinical outcomes.
"These results confirm that the use of SPY can improve the outcome of heart bypass surgery and that identifying problems in the operating room with the SPY System can lead to significantly improved clinical results," said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq Technologies Inc. "Complications after surgery can lead to poor recovery, high risk repeat surgeries and higher costs of care. These results are very important and the STS scientific meeting is the leading forum for presentation and discussion of important advancements in care among cardiac surgeons."
The primary objective of this comparative study which included a total of 2738 patients of which 384 (192 matched pairs) CABG patients were evaluated to determine if perioperative (during surgery) patency assessment with SPY fluorescence angiography decreased the amount of myocardial injury during or after CABG surgery.
"Up to half of all significant perioperative myocardial infarctions are related to graft failure. The immediate and long term success of coronary surgery is dependent on the construction of a technically perfect anastomosis with a high quality conduit to an appropriate target coronary vessel, yet despite systematic improvements in the outcomes of coronary surgery, modern coronary bypass series continue to report perioperative graft occlusions rates as high as 3-10%," said Nimesh Desai, MD, PhD., lead author and cardiac surgeon at Sunnybrook Health Sciences Centre. "A reliable and well-validated method to assess graft patency in coronary surgery represents an important opportunity for improving quality assurance in coronary bypass. The results of the study demonstrate that intra-operative angiography with graft revision led to significantly fewer perioperative myocardial injuries by enzymatic criteria. This data supports the increasing use of the intra-operative graft assessment to verify graft patency. These very early graft failures are usually related to technical problems at graft anastomosis sites and may be correctable if recognized intra-operatively."
About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ ) develops and commercializes medical imaging devices for use in the operating room. Novadaq's proprietary imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. Novadaq's SPY Intra-operative Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open-heart surgery. Novadaq's OPTTX® System which received CE Mark approval in November 2006, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The HELIOS(TM) System, which received FDA clearance in January 2007, is the first fluorescent imaging system available for use during plastic reconstructive surgery allowing surgeons to evaluate pre- and intra-operative blood flow, as well as post-surgery perfusion. Novadaq's LUNA(TM) system is designed to enable surgeons to visualize nerve bundles during the course of urological and neurological procedures. LUNA has been granted a license for use by Health Canada. For more information, please visit the company's website at www.novadaq.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release was prepared by management from information available to January 31, 2007.
Source: Novadaq Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.